Search

Your search keyword '"Smits, Pieter"' showing total 121 results

Search Constraints

Start Over You searched for: Author "Smits, Pieter" Remove constraint Author: "Smits, Pieter" Journal journal of the american college of cardiology (jacc) Remove constraint Journal: journal of the american college of cardiology (jacc)
121 results on '"Smits, Pieter"'

Search Results

1. TCT-130 Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: Insights From the LANDMARK Trial.

2. TCT-915 Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial.

3. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.

4. 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial)

5. Catheter-Based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: Clinical experience with Six-Month Follow-Up

9. TWO YEAR RESULTS FROM THE COMPARE-ACUTE TRIAL.

11. TCT-70 Final 5 year results from the COMPARE II trial: comparison between the durable polymer coated everolimus-eluting Xience/Promus stent and the biodegradable polymer coated biolimus-eluting Nobori stent in all comer population.

15. TCT-1 High number of angiographic significant lesions are FFR negative in STEMI patients with multi-vessel disease: preliminary insight into the COMPARE-ACUTE trial.

19. IMPACT OF GEOGRAPHICAL VARIATION BETWEEN EUROPE AND ASIA ON CLINICAL OUTCOMES IN PATIENTS WITH HIGH BLEEDING RISK (HBR) AND BIODEGRADABLE-POLYMER SIROLIMUSELUTING CORONARY STENT: A SUBSTUDY OF MASTER DAPT.

27. Assessing Microvascular Dysfunction in Angina With Unobstructed Coronary Arteries: JACC Review Topic of the Week.

30. Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention.

31. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention.

32. TCT-28 Pharmacodynamic Response, Early Reperfusion, and Clinical Outcomes to Pre-Hospital Prasugrel Administration in Diabetic Patients Presenting With STEMI—A COMPARE CRUSH Subanalysis.

33. TCT-23 Influence of the Circadian Clock on the Pharmacodynamic Effect of Prasugrel in Patients Presenting With ST-Segment Elevation Myocardial Infarction—A COMPARE CRUSH Subanalysis.

34. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.

35. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.

37. TCT-316 Impact of Geographic Variation on the Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent: Results From the PIONEER III Clinical Trial in North America, Europe, and Japan.

38. TCT-46 Pre-Hospital Crushed Versus Integral Prasugrel Loading Dose in Patients Presenting With Anterior ST-Segment Elevation Myocardial Infarction—A COMPARE CRUSH Subanalysis.

41. TCT-291 Correlation Between Reduced Infarct-Related Artery Patency on Initial Angiography and Post-PCI Reperfusion TIMI Flow in STEMI Patients—A COMPARE CRUSH Subanalysis.

42. TCT-164 Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial.

44. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

45. Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

46. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: Evidence From a Comprehensive Network Meta-Analysis.

47. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.

48. Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction: 1-Year Results of the Randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) Trial

49. Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes

50. 6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm

Catalog

Books, media, physical & digital resources